Slide 1: Strong Growth, Bright Future. H1 FY21 Investor Presentation
USCOM Strong Growth, Bright Future. H1 FY21 Investor Presentation Prof. Rob Phillips 24th February 2021 ASX: UCM
Slide 2: Strong growth, bright future.
“ Uscom continues its mission to create life saving non-invasive cardiovascular and pulmonary technologies to improve care of We are proud of the diseases which are responsible for more than 75% of all global contributions we have delivered to global health mortality. Developing world leading device
Slide 3: Cash Flow Positive with Profit
USCOM ASX Listed Cash Flow Positive Premium global cardiovascular with Profit and pulmonary medical Record Operating Cash Inflow technology China and Europe Profit Patented Apex Global Vision and Technologies Ambitions World leading digital Operations in Sydney, Singapore, technologies in cardiac, v
Slide 4: Global Expansion
GLOBAL EXPANSION • London • Beijing • Budapest • LA Operations Sydney Singapore • Singapore Beijing Budapest Offices Auckland • Sydney London • Auckland LA China Embedded, Globally Diversified Poised for growth, and hedged for politics and currency
Slide 5: Uscom Global: Smart & Capable
Uscom Global Smart & Capable Rob Phillips Nick Schicht Teresa Guo Lucy Lu Scott Huang Denise Pater Rik Denicke George Ferenczi Leo Luo Scarlett Zhang Szabolcs Reichardt Richard Scott Zsofia Kertesz Crystal Lin Daniel Gizella Susanna Sun Curt Grosse Andrea Marosan Antonio Ferrario Uzair Khyshzai Cath
Slide 6: H1 Results
H1 20 v H1 21 2021: H1 20 H1 21 ASX:UCM ↑ 153% H1 RESULTS 3.00 ↑ 187% 2.77 2.81 Sale of Goods $2.30M up 232% ↑ 232% 2.50 2.30 Revenue and Income $2.77M up 2.00 187% Receipts from Customers 1.50 $2.81M up 153% 1.11 $M AUD 1.00 0.96 Net cash flow up $1.14M ↑ $1.14M 0.68 CY20 Revenue and Inco
Slide 7: Trend Results: UCM Total Receipts
UCM Total Receipts 2021: $6.00 $6.0 TREND RESULTS $5.00 ASX:UCM $4.60 $4.00 $3.64 Growth Trend Continues $3.50 CY20 $6.09m up 95% $M AUD $2.94 $2.86 $3.00 CY20 cash inflow $0.8M $2.04 $2.00 $1.38 $1.01 $1.00 $0.86 $0.00 2012 2013 2014 2015 2016 2017 2018 2019 2020 CY2020 H1 FY21 and 9 prior ye
Slide 8: Regional and Product Sales
2020: REGIONAL AND PRODUCT SALES ASX:UCM USCOM 1A - lead product China - major Uscom market BP+ and SpiroSonic sales will increase as regulatory approvals are received in China, Europe, SE Asia and the US. Strong growth, bright future.
Slide 9: Uscom Products
USCOM PRODUCTS Uscom Products USCOM 1A SpiroReporter MyAIR APP USCOM 1A software Asthma, COPD, OLD Uscom Advanced Haemodynamic APP and COVID Heart failure, hypertension, sepsis, fluid Blue Sky Uscom eHealth Ecosystem BP+ Reporter Hypertension, vascular health Blue Sky VENTITEST-S Uscom eHealth Ecosy
Slide 10: Uscom Market Opportunity
MASSIVE GLOBAL MARKETS Uscom Market Opportunity USCOM 1A Massive Clinical Markets • USCOM1A: ~USD $32 billion by 2025 • BP+: ~USD 22 billion by 2025 • SpiroSonic: ~USD 47 billion by 2025 • VentiTest: ~USD 27 billion by 2027 • Total Markets - $128 billion by 2027 Premium Medical Markets 0 10 20 30 40
Slide 11: 2021 Growth Drivers
2021 GROWTH DRIVERS New Products More Distributors • SpiroSonic and BP+ approvals for China SE Asia and US • Uscom China • VENTITEST and VENTITEST-S sales • SE Asia • Blue Sky eHealth Ecosystem – • New European and US recurrent digital cloud based distribution models CORPORATE revenues Sales Growth
Slide 12: Summary
SUMMARY High organic Superior quality World leading devices Rapidly growing revenue growth business model and quality brands fundamentals Increasing cash reserves Imminent new Debt free Rare combination of revenues quality, growth and value Strong growth, bright future.
Slide 13: Value Investors: UCM
VALUE INVESTORS: UCM “Total receipts up 600% over 8 years, share price unchanged.” $6.0 $6.00 Revenue and Income 8yrs Share Price 8yrs $5.00 $4.60 $4.00 $3.64 $3.50 $M AUD $2.94 $2.86 $3.00 $2.04 $2.00 $1.38 $1.01 $1.00 $0.86 $0.00 2012 2013 2014 2015 2016 2017 2018 2019 2020 CY2020 Strong growth, b
Slide 14: Conclusion
CONCLUSION “Growing fundamentals has never been more important to value investors” “We continue driving strong growth fundamentals and accumulating cash, while investing in expanded international operations and new subsidiaries, and finalising multiple international regulatory approvals for new prod
Slide 15: USCOM
USCOM Strong Growth, Bright Future H1 FY21 Investor Presentation Prof. Rob Phillips 24th February 2021 ASX: UCM